Oramed Pharmaceuticals Inc. (ORMP) Financials Nov 14, 2014, 3:59 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Oramed Pharmaceuticals Inc.
Fiscal year is September-August. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 30,488 31,862 28,303 14,737 5,379
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 30,488 31,862 28,303 14,737 5,379
Depreciation 30,488 31,862 28,303 14,737 5,379
Amortization of Intangibles 0 0 0 0 0
Gross Income (30,488) (31,862) (28,303) (14,737) (5,379)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 2.75M 2.94M 2.41M 2.87M 4.3M
Research & Development 1.52M 1.46M 1.13M 1.68M 2.27M
Other SG&A 1.23M 1.48M 1.28M 1.19M 2.03M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 197,412 184,254 (44,699)
EBIT after Unusual Expense 0 0 (197,412) (184,254) 44,699
Non Operating Income/Expense 0 0 1.01M (199,123) (196,378)
Non-Operating Interest Income 38,602 24,692 33,232 13,126 18,728
Equity in Affiliates (Pretax) - - 0 0 0
Interest Expense 17,555 14,544 0 0 0
Gross Interest Expense 17,555 14,544 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income (2.76M) (2.96M) (1.59M) (3.25M) (4.44M)
Income Tax (2,597) 14,971 (23,980) 90,218 (205,062)
Income Tax - Current Domestic - - - - (12,960)
Income Tax - Current Foreign - - - - (192,102)
Income Tax - Deferred Domestic - - - - 0
Income Tax - Deferred Foreign - - - - 0
Income Tax Credits - - - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (2.76M) (2.98M) (1.56M) (3.34M) (4.23M)
Minority Interest Expense 0 0 0 0 0
Net Income (2.76M) (2.98M) (1.56M) (3.34M) (4.23M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (2.76M) (2.98M) (1.56M) (3.34M) (4.23M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (2.76M) (2.98M) (1.56M) (3.34M) (4.23M)
EPS (Basic) (0.60) (0.60) (0.24) (0.60) (0.59)
Basic Shares Outstanding 4.72M 4.78M 5.42M 5.88M 7.21M
EPS (Diluted) (0.60) (0.60) (0.24) (0.60) (0.59)
Diluted Shares Outstanding 4.72M 4.78M 5.42M 5.88M 7.21M
EBITDA (2.75M) (2.94M) (2.41M) (2.87M) (4.3M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Oramed Pharmaceuticals Inc.
Fiscal year is September-August. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A 30,488 31,862 28,303 14,737 5,379
COGS excluding D&A 0 0 0 0 0
Depreciation & Amortization Expense 30,488 31,862 28,303 14,737 5,379
Depreciation 30,488 31,862 28,303 14,737 5,379
Amortization of Intangibles 0 0 0 0 0
Gross Income (30,488) (31,862) (28,303) (14,737) (5,379)
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 2.75M 2.94M 2.41M 2.87M 4.3M
Research & Development 1.52M 1.46M 1.13M 1.68M 2.27M
Other SG&A 1.23M 1.48M 1.28M 1.19M 2.03M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 0 197,412 184,254 (44,699)
EBIT after Unusual Expense 0 0 (197,412) (184,254) 44,699
Non Operating Income/Expense 0 0 1.01M (199,123) (196,378)
Non-Operating Interest Income 38,602 24,692 33,232 13,126 18,728
Equity in Affiliates (Pretax) - - 0 0 0
Interest Expense 17,555 14,544 0 0 0
Gross Interest Expense 17,555 14,544 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income (2.76M) (2.96M) (1.59M) (3.25M) (4.44M)
Income Tax (2,597) 14,971 (23,980) 90,218 (205,062)
Income Tax - Current Domestic - - - - (12,960)
Income Tax - Current Foreign - - - - (192,102)
Income Tax - Deferred Domestic - - - - 0
Income Tax - Deferred Foreign - - - - 0
Income Tax Credits - - - - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (2.76M) (2.98M) (1.56M) (3.34M) (4.23M)
Minority Interest Expense 0 0 0 0 0
Net Income (2.76M) (2.98M) (1.56M) (3.34M) (4.23M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (2.76M) (2.98M) (1.56M) (3.34M) (4.23M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (2.76M) (2.98M) (1.56M) (3.34M) (4.23M)
EPS (Basic) (0.60) (0.60) (0.24) (0.60) (0.59)
Basic Shares Outstanding 4.72M 4.78M 5.42M 5.88M 7.21M
EPS (Diluted) (0.60) (0.60) (0.24) (0.60) (0.59)
Diluted Shares Outstanding 4.72M 4.78M 5.42M 5.88M 7.21M
EBITDA (2.75M) (2.94M) (2.41M) (2.87M) (4.3M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
